Throughout the 1920s, prices on the U.S. stock exchange rose exponentially, however, by the end of the decade, uncontrolled growth and a stock market propped up by speculation and borrowed money proved unsustainable, resulting in the Wall Street Crash of October 1929. This set a chain of events in motion that led to economic collapse - banks demanded repayment of debts, the property market crashed, and people stopped spending as unemployment rose. Within a year the country was in the midst of an economic depression, and the economy continued on a downward trend until late-1932.

It was during this time where Franklin D. Roosevelt (FDR) was elected president, and he assumed office in March 1933 - through a series of economic reforms and New Deal policies, the economy began to recover. Stock prices fluctuated at more sustainable levels over the next decades, and developments were in line with overall economic development, rather than the uncontrolled growth seen in the 1920s. Overall, it took over 25 years for the Dow Jones value to reach its pre-Crash peak.

Interactive chart of the Dow Jones Industrial Average (DJIA) stock market index for the last 100 years. Historical data is inflation-adjusted using the headline CPI and each data point represents the month-end closing value. The current month is updated on an hourly basis with today's latest value.

The Dow Jones Industrial Average (DJIA) is a stock market index used to analyze trends in the stock market. While many economists prefer to use other, market-weighted indices (the DJIA is price-weighted) as they are perceived to be more representative of the overall market, the Dow Jones remains one of the most commonly-used indices today, and its longevity allows for historical events and long-term trends to be analyzed over extended periods of time. Average changes in yearly closing prices, for example, shows how markets developed year on year. Figures were more sporadic in early years, but the impact of major events can be observed throughout. For example, the occasions where a decrease of more than 25 percent was observed each coincided with a major recession; these include the Post-WWI Recession in 1920, the Great Depression in 1929, the Recession of 1937-38, the 1973-75 Recession, and the Great Recession in 2008.

Interactive chart of the S&P 500 stock market index since 1927. Historical data is inflation-adjusted using the headline CPI and each data point represents the month-end closing value. The current month is updated on an hourly basis with today's latest value.

The Long Depression was, by a large margin, the longest-lasting recession in U.S. history. It began in the U.S. with the Panic of 1873, and lasted for over five years. This depression was the largest in a series of recessions at the turn of the 20th century, which proved to be a period of overall stagnation as the U.S. financial markets failed to keep pace with industrialization and changes in monetary policy. Great Depression The Great Depression, however, is widely considered to have been the most severe recession in U.S. history. Following the Wall Street Crash in 1929, the country's economy collapsed, wages fell and a quarter of the workforce was unemployed. It would take almost four years for recovery to begin. Additionally, U.S. expansion and integration in international markets allowed the depression to become a global event, which became a major catalyst in the build up to the Second World War. Decreasing severity When comparing recessions before and after the Great Depression, they have generally become shorter and less frequent over time. Only three recessions in the latter period have lasted more than one year. Additionally, while there were 12 recessions between 1880 and 1920, there were only six recessions between 1980 and 2020. The most severe recession in recent years was the financial crisis of 2007 (known as the Great Recession), where irresponsible lending policies and lack of government regulation allowed for a property bubble to develop and become detached from the economy over time, this eventually became untenable and the bubble burst. Although the causes of both the Great Depression and Great Recession were similar in many aspects, economists have been able to use historical evidence to try and predict, prevent, or limit the impact of future recessions.

On October 29, 1929, the U.S. experienced the most devastating stock market crash in it's history. The Wall Street Crash of 1929 set in motion the Great Depression, which lasted for twelve years and affected virtually all industrialized countries. In the United States, GDP fell to it's lowest recorded level of just 57 billion U.S dollars in 1933, before rising again shortly before the Second World War. After the war, GDP fluctuated, but it increased gradually until the Great Recession in 2008. Real GDP Real GDP allows us to compare GDP over time, by adjusting all figures for inflation. In this case, all numbers have been adjusted to the value of the US dollar in FY2012. While GDP rose every year between 1946 and 2008, when this is adjusted for inflation it can see that the real GDP dropped at least once in every decade except the 1960s and 2010s. The Great Recession Apart from the Great Depression, and immediately after WWII, there have been two times where both GDP and real GDP dropped together. The first was during the Great Recession, which lasted from December 2007 until June 2009 in the US, although its impact was felt for years after this. After the collapse of the financial sector in the US, the government famously bailed out some of the country's largest banking and lending institutions. Since recovery began in late 2009, US GDP has grown year-on-year, and reached 21.4 trillion dollars in 2019. The coronavirus pandemic and the associated lockdowns then saw GDP fall again, for the first time in a decade. As economic recovery from the pandemic has been compounded by supply chain issues, inflation, and rising global geopolitical instability, it remains to be seen what the future holds for the U.S. economy.

In 2024, ** percent of adults in the United States invested in the stock market. This figure has remained steady over the last few years, and is still below the levels before the Great Recession, when it peaked in 2007 at ** percent. What is the stock market? The stock market can be defined as a group of stock exchanges, where investors can buy shares in a publicly traded company. In more recent years, it is estimated an increasing number of Americans are using neobrokers, making stock trading more accessible to investors. Other investments A significant number of people think stocks and bonds are the safest investments, while others point to real estate, gold, bonds, or a savings account. Since witnessing the significant one-day losses in the stock market during the Financial Crisis, many investors were turning towards these alternatives in hopes for more stability, particularly for investments with longer maturities. This could explain the decrease in this statistic since 2007. Nevertheless, some speculators enjoy chasing the short-run fluctuations, and others see value in choosing particular stocks.

The depression treatment market is valued at USD 11 billion in 2024. It is anticipated to grow at a CAGR of 5.2% during the assessment period and reach a value of USD 18.3 billion by 2034.

Country-wise Analysis

Depression MDD Drugs Market Outlook

The global Depression MDD Drugs market size is expected to witness significant growth, with estimations indicating that it will reach approximately USD 18.9 billion in 2023 and is projected to grow at a CAGR of 3.5% to reach USD 25.8 billion by 2032. This growth is primarily driven by the rising prevalence of depression and major depressive disorder (MDD) globally, coupled with increasing awareness and development of novel therapeutic options.

One of the critical growth factors for the Depression MDD Drugs market is the increasing incidence of mental health disorders worldwide. According to the World Health Organization (WHO), depression affects more than 264 million people globally. This growing prevalence is propelling the demand for effective therapeutic options. Additionally, societal changes, such as increasing stress levels due to work-life imbalance and economic uncertainties, are contributing to a higher incidence of depression, further catalyzing market growth.

Another significant growth driver is advancements in pharmaceutical research and development. The last few decades have seen considerable progress in understanding the pathophysiology of depression, leading to the development of innovative drug classes such as SSRIs, SNRIs, and atypical antipsychotics. These advancements are improving treatment outcomes and broadening the therapeutic landscape, making it more accessible for patients with varying degrees and types of depression.

Furthermore, increasing awareness and reduced stigma surrounding mental health are encouraging more individuals to seek treatment. Public health campaigns and improved mental health education are making it easier for patients to recognize symptoms and seek early intervention. This is particularly important as early and effective treatment can significantly improve the prognosis for individuals with MDD, thereby boosting the demand for depression drugs.

The regional outlook of the Depression MDD Drugs market indicates robust growth prospects across various geographies. North America, particularly the United States, holds a significant share due to high healthcare expenditure, advanced healthcare infrastructure, and a greater awareness of mental health issues. Europe also represents a substantial market, with countries like Germany and the UK investing significantly in mental health services. Meanwhile, Asia Pacific is anticipated to exhibit the highest growth rate due to rising healthcare expenditure, increasing prevalence of mental health disorders, and a growing acceptance of western medical practices.

Sertraline HCl, a widely recognized selective serotonin reuptake inhibitor (SSRI), plays a pivotal role in the treatment of major depressive disorder (MDD). As a cornerstone in antidepressant therapy, Sertraline HCl is favored for its efficacy and relatively mild side effect profile compared to older antidepressants. Its ability to enhance serotonin levels in the brain makes it an effective option for alleviating symptoms of depression. The continued trust in Sertraline HCl among healthcare providers and patients underscores its importance in the therapeutic landscape, contributing significantly to the robust market share of SSRIs.

Drug Class Analysis

Selective Serotonin Reuptake Inhibitors (SSRIs) are the most commonly prescribed class of drugs for treating depression and MDD. SSRIs work by increasing the levels of serotonin in the brain, a neurotransmitter associated with mood regulation. The widespread acceptance and usage of SSRIs can be attributed to their relatively favorable side effect profile compared to older antidepressants. Popular SSRIs include fluoxetine, sertraline, and citalopram, which have been shown to be effective in alleviating symptoms of depression. The familiarity and trust in SSRIs among healthcare professionals and patients alike continue to drive their robust market share.

Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) represent another significant segment within the Depression MDD Drugs market. SNRIs target both serotonin and norepinephrine neurotransmitters, providing a dual mechanism of action that can be particularly effective for patients who do not respond adequately to SSRIs. Drugs like venlafaxine and duloxetine fall under this category and have gained substantial market traction due to their efficacy in treating not only depression but also anxiety disorders, broadening their therapeutic a

The global depression drug market is projected to reach a value of 15.24 billion by 2033, growing at a CAGR of 3.85% from 2025 to 2033. The market is driven by the increasing prevalence of depression, rising awareness of mental health issues, and the development of new and more effective treatments. Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) are the most commonly prescribed antidepressants, while oral administration is the most prevalent route of administration. Key players in the market include Eli Lilly, AstraZeneca, Sanofi, and Roche. North America held the largest share of the market in 2025, followed by Europe and Asia Pacific. The growing prevalence of depression, high healthcare spending, and the presence of major pharmaceutical companies contribute to North America's dominance. However, Asia Pacific is expected to witness the fastest growth during the forecast period due to the increasing awareness of mental health issues, rising disposable income, and expanding healthcare infrastructure in developing countries within the region. Recent developments include: Recent developments in the Depression Drug Market have been influenced by a variety of factors, including an increasing focus on mental health awareness and the integration of innovative therapies. The emergence of new antidepressants, such as those targeting specific neurotransmitter systems, demonstrates the ongoing research efforts to improve treatment outcomes. Additionally, the push towards personalized medicine is shaping the way pharmaceuticals are developed, as companies seek to tailor treatments based on individual patient profiles. In recent months, regulatory agencies have accelerated the approval processes for several promising drugs, reflecting a growing recognition of the need for effective treatment options. Furthermore, the COVID-19 pandemic has underscored the urgency of addressing mental health challenges, leading to increased funding for research and development in this domain. Market players are therefore positioning themselves through strategic collaborations and partnerships to enhance their portfolios and explore emerging therapeutic avenues. Efforts to develop digital therapeutics and telehealth services are gaining traction, complementing traditional treatment modalities and expanding access to care for patients worldwide. These trends indicate a dynamic landscape that remains responsive to societal needs and technological advancements.. Key drivers for this market are: · Increasing prevalence of depression · Growing interest in personalized medicine · Expansion of teletherapy services · Rising demand for alternative treatments · Development of novel drug formulations. Potential restraints include: Growing prevalence of depression, Increasing Rapid investment; Shift towards personalized medicine; Rise in mental health awareness; & Expanding telehealth services.

Depression Treatment Market Outlook

In 2023, the global depression treatment market size was valued at approximately USD 14.9 billion. The market is expected to grow at a compound annual growth rate (CAGR) of 7.2% from 2024 to 2032, reaching an estimated value of USD 28.9 billion by the end of the forecast period. The growth of this market is driven by an increasing prevalence of depression globally, rising awareness about mental health, and advancements in treatment methodologies.

The growing prevalence of depression and other mental health disorders is a significant factor propelling the market. According to the World Health Organization (WHO), more than 264 million people worldwide suffer from depression. The increasing awareness about mental health issues and the importance of early treatment has led to higher diagnosis rates, driving demand for various depression treatments. Furthermore, the stigma surrounding mental health is gradually diminishing, encouraging more individuals to seek help and treatment.

Technological advancements and innovations in the field of depression treatment are also contributing to market growth. The development of new and effective medications, brain stimulation therapies, and digital mental health solutions are expanding the range of treatment options available to patients. For instance, the advent of digital therapies and mobile health applications has made mental health support more accessible and personalized. Additionally, ongoing research and clinical trials are expected to introduce novel treatments and improve existing therapies, further boosting the market.

Government initiatives and policies aimed at improving mental health services are playing a crucial role in market expansion. Many countries are investing in mental health infrastructure, launching awareness campaigns, and implementing supportive policies to ensure better access to mental health care. For example, the Mental Health Parity and Addiction Equity Act in the United States mandates that insurance coverage for mental health services should be on par with physical health services. Such initiatives are likely to increase the number of individuals seeking treatment for depression.

Serotonin Syndrome Treatment is an important consideration in the context of depression treatment, particularly with the use of certain antidepressants. This condition occurs when there is an excess of serotonin in the brain, often due to drug interactions or overdose of serotonergic medications. It is crucial for healthcare providers to recognize the symptoms, which can range from mild to life-threatening, and to manage the condition promptly. Treatment typically involves discontinuing the offending medication and providing supportive care. In severe cases, medications such as benzodiazepines or serotonin antagonists may be used to alleviate symptoms. Understanding and addressing serotonin syndrome is essential for ensuring patient safety and optimizing treatment outcomes in the depression treatment market.

Regionally, North America holds a significant share of the depression treatment market, driven by high awareness levels, advanced healthcare infrastructure, and supportive government policies. Europe also represents a substantial market due to its well-established healthcare systems and growing focus on mental health. The Asia Pacific region is expected to witness the highest growth rate, attributed to increasing awareness, improving healthcare infrastructure, and rising prevalence of depression. However, challenges such as limited access to mental health services in certain developing regions could impede market growth.

Medications Analysis

Medications are one of the primary treatment types in the depression treatment market. This segment includes various classes of antidepressants such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs). SSRIs are the most commonly prescribed due to their efficacy and relatively mild side effect profile. Drugs like fluoxetine and sertraline dominate this sub-segment, driving significant revenue.

The medications segment benefits substantially from continuous pharmaceutical research and development. The introduction of newer antidepressants with improved efficacy and fewer side effects has expanded treatment options. Additionally, the ongoing pa

Graph and download economic data for Real-time Sahm Rule Recession Indicator (SAHMREALTIME) from Dec 1959 to Jun 2025 about recession indicators, academic data, and USA.

The Postpartum Depression Drugs Market Report Segments the Industry Into by Drug Class (Neuroactive-Steroid Antidepressants, Selective Serotonin Re-Uptake Inhibitors and More), by Route of Administration (Oral, Intravenous and More), by End Users (Hospitals and Clinics, Specialty Centers, Others), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

The global depression drugs market size reached USD 19.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 25.1 Billion by 2033, exhibiting a growth rate (CAGR) of 2.9% during 2025-2033. The growing cases of depression among the masses due to sedentary lifestyle and stress, increasing advancements in drug formulation and delivery techniques, and rising preferences for digital therapeutics, such as mobile apps and online therapy platforms, are some of the factors impelling the market growth.

Depression Drugs Market Outlook

The global depression drugs market size was valued at approximately USD 18 billion in 2023 and is projected to reach around USD 27 billion by 2032, growing at a CAGR of 4.6% during the forecast period. This growth is primarily driven by the increasing prevalence of depression and other mental health disorders worldwide, coupled with the rising awareness and improving healthcare infrastructure that facilitate the diagnosis and treatment of these conditions. Other contributing factors include advancements in pharmaceutical research and development, which have led to the introduction of more effective and safer medications, and the growing acceptance of mental health issues as a significant healthcare concern that needs immediate addressing.

One of the major growth factors in the depression drugs market is the increasing prevalence of depression itself, which is recognized as one of the leading causes of disability globally. According to the World Health Organization, depression affects more than 264 million people worldwide, and the numbers are expected to rise due to factors such as urbanization, social isolation, economic pressure, and the aftermath of global events like the COVID-19 pandemic. The rising awareness and the destigmatization of mental health issues have prompted more individuals to seek professional help, thus increasing demand for effective pharmacological treatments. Moreover, the implementation of public health initiatives aimed at improving mental health awareness and accessibility to treatment further propels market growth.

Technological advancements in drug development have also significantly contributed to the expansion of the depression drugs market. Pharmaceutical companies are investing heavily in research and development to discover novel therapeutic molecules that provide better efficacy and fewer side effects compared to traditional antidepressants. The emergence of personalized medicine and the growing understanding of genetic factors in depression have led to more targeted drug therapies, which are expected to drive market growth in the coming years. Additionally, the development of new drug formulations, such as extended-release tablets and liquid formulations, caters to a broader patient demographic and improves treatment adherence.

The regulatory environment and healthcare policies across various regions play a crucial role in shaping the depression drugs market. In many developed countries, there is a strong emphasis on mental health within public health systems, leading to better reimbursement policies and increased funding for mental health research. However, emerging economies, particularly in the Asia Pacific and Latin America regions, are witnessing significant improvements in healthcare infrastructure and mental health awareness. Governments and non-governmental organizations are working hand in hand to address mental health challenges, which is expected to boost the market in these regions. Furthermore, the expansion of telemedicine and digital health solutions post-pandemic has improved access to mental health services, thereby increasing patient access to depression medications.

Drug Type Analysis

The depression drugs market is segmented by drug type, including Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Atypical Antidepressants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors (MAOIs), and others. SSRIs hold a significant share of the market due to their favorable safety profile and efficacy in treating various depression symptoms. They are often considered the first-line treatment for depression because they typically have fewer side effects compared to older classes of antidepressants. The widespread use of SSRIs can be attributed to their ability to effectively increase serotonin levels in the brain, which helps improve mood and emotional stability.

SNRIs are also gaining traction in the depression drugs market due to their dual action mechanism, which targets both serotonin and norepinephrine neurotransmitters. This dual reuptake inhibition is believed to be advantageous for patients who do not respond adequately to SSRIs. SNRIs, such as venlafaxine and duloxetine, are particularly effective in treating major depressive disorder and have shown promise in managing co-occurring anxiety disorders, thereby expanding their application scope. The market share of SNRIs is expected to grow steadily as more clinical evidence supports their efficacy and safety.

Atypical antidepressants, which include a diverse range of drugs with v

Depression Treatment Device Market Outlook

The global depression treatment device market size was valued at approximately USD 1.5 billion in 2023 and is projected to reach around USD 3.5 billion by 2032, expanding at a compound annual growth rate (CAGR) of 10.2% during the forecast period. This growth is driven by a combination of increasing prevalence of depression, advancements in medical technology, and rising awareness about mental health.

One of the key growth factors for the depression treatment device market is the rising incidence of depression worldwide. According to the World Health Organization, depression is a leading cause of disability globally, affecting over 264 million people. This high prevalence is creating a substantial demand for effective treatment options, including devices designed to alleviate symptoms of depression. Additionally, the increasing recognition of mental health issues and the reduction of stigma associated with seeking help for such conditions are encouraging more individuals to pursue treatment, thereby driving market growth.

Technological advancements in medical devices are another significant factor propelling the growth of this market. Innovations such as Transcranial Magnetic Stimulation (TMS), Cranial Electrotherapy Stimulation (CES), and Deep Brain Stimulation (DBS) devices have shown promising results in treating depression, especially in patients who do not respond well to traditional therapies like medication and psychotherapy. These advancements have not only improved the efficacy of treatment but also made these devices more accessible and user-friendly, further boosting market growth.

The growing support and investment from both public and private sectors in mental health initiatives are also contributing to the expansion of the depression treatment device market. Governments and organizations worldwide are increasingly recognizing the importance of mental health and are allocating substantial funds to research and development, awareness programs, and the implementation of mental health services. This increased funding is facilitating the development and commercialization of new and improved depression treatment devices, thereby fostering market growth.

From a regional perspective, North America is expected to hold the largest share of the depression treatment device market, followed by Europe and the Asia Pacific region. This can be attributed to the high prevalence of depression, robust healthcare infrastructure, and significant investments in mental health services in these regions. Furthermore, the increasing adoption of advanced medical technologies and the presence of key market players in these regions are also driving growth. The Asia Pacific region, in particular, is anticipated to witness the highest growth rate during the forecast period, owing to the rising awareness about mental health and improving healthcare infrastructure.

Product Type Analysis

The depression treatment device market is segmented into various product types, including Cranial Electrotherapy Stimulation (CES) Devices, Transcranial Magnetic Stimulation (TMS) Devices, Vagus Nerve Stimulation (VNS) Devices, Deep Brain Stimulation (DBS) Devices, and Others. Each of these product types has unique features and applications that cater to different patient needs and preferences.

Cranial Electrotherapy Stimulation (CES) Devices are non-invasive devices that deliver small electrical currents to the brain to stimulate neurotransmitter production. These devices have gained popularity due to their ease of use, minimal side effects, and effectiveness in reducing anxiety and depression symptoms. CES devices are particularly beneficial for patients who prefer non-pharmacological treatment options or those who have not responded well to medication.

Transcranial Magnetic Stimulation (TMS) Devices use magnetic fields to stimulate nerve cells in the brain, which can improve symptoms of depression. TMS is typically used for patients with treatment-resistant depression, meaning they have not responded to traditional therapies. The non-invasive nature of TMS, combined with its relatively quick treatment sessions and minimal side effects, has made it a popular choice among healthcare providers and patients alike.

Vagus Nerve Stimulation (VNS) Devices involve the implantation of a small device that sends electrical impulses to the vagus nerve, which can help regulate mood. VNS is generally considered for patients with severe, treatment-resistant depression who have not had suc

The Depression Therapeutics market has gained significant attention in recent years, reflecting the growing global concern over the increasing prevalence of depression and related mental health disorders. With approximately 280 million people suffering from depression worldwide, the need for effective therapeutic so

In this paper, we document trends in credit use across income groups in the period surrounding the Great Recession. We investigate trends in access to different credit markets, including mortgages, home equity, automobiles, and student loans. We disentangle growth rates of new market entrants from the aggregates and analyze overall as well as within-county growth rate differentials across income strata. Our findings may provide insight into the financial well-being of different income groups in the context of the Great Recession.

The global treatment-resistant depression (TRD) market, while facing challenges, presents significant growth opportunities. The market's value in 2025 is estimated at $XX million (replace XX with a reasonable estimate based on available data and market research reports for similar markets; for example, if a related market shows a similar size and growth, you could use that as a baseline). A compound annual growth rate (CAGR) of 4.00% from 2025 to 2033 projects substantial market expansion driven by several factors. The increasing prevalence of depression, coupled with the rising awareness of TRD and its distinct treatment needs, fuels market growth. Technological advancements leading to the development of novel therapies and improved diagnostic tools are further bolstering market expansion. The adoption of personalized medicine approaches, targeting specific genetic or biochemical profiles in TRD patients, is also expected to significantly impact market growth in the coming years. However, the high cost of innovative TRD treatments and their potential side effects pose significant restraints. Furthermore, the complexities associated with diagnosing TRD and the limitations of current treatment options contribute to slower growth in some regions. The market is segmented by drug class (SSRIs, MAOIs, TCAs, and others) and distribution channel (hospital, retail, and online pharmacies). North America and Europe currently dominate the market due to higher healthcare expenditure and greater awareness. However, emerging markets in Asia-Pacific are projected to witness faster growth rates owing to increasing healthcare investment and rising prevalence of depression in these regions. The competitive landscape is shaped by major pharmaceutical companies such as AstraZeneca, Pfizer, GlaxoSmithKline, Eli Lilly, and Bristol-Myers Squibb, along with several emerging players focusing on innovative treatment approaches. The strategic partnerships and collaborations among these companies are driving the development of next-generation therapies, while also fueling the market's competitiveness. Future growth will hinge upon advancements in drug discovery, improved patient access to treatment, and the development of effective strategies to address the challenges associated with diagnosis and treatment adherence. Market players are also increasingly focusing on digital health solutions to improve patient outcomes and treatment compliance, thereby contributing to market growth. Regulatory approvals for new drugs and the pricing dynamics within the healthcare sector will also influence future market trends. Recent developments include: In July 2022, Abbott received the United States Food and Drug Administration's approval to use its deep brain stimulators (DBS) device for treatment-resistant depression (TRD),, In December 2021, Dr. Reddy's launched following the United States Food and Drug Administration approval, the product equivalent to Venlafaxine extended release, an anti-depressant tablet.. Key drivers for this market are: Rise in Prevalence of Depression, Increase in chronic diseases. Potential restraints include: Rise in Prevalence of Depression, Increase in chronic diseases. Notable trends are: The Retail Pharmacies Segment is Expected to Hold a Major Market Share in the Treatment- Resistant Depression Market.

The anxiety and depression treatment market was valued at USD 12.18 Billion in 2024, driven by the rising prevalence of mental health disorders across the 8 major markets. The market is anticipated to grow at a CAGR of 3.10% during the forecast period of 2025-2034 to achieve a value of USD 16.53 Billion by 2034. The growing awareness and acceptance of mental health conditions are driving increased demand for innovative treatments for anxiety and depression.